Trial Profile
A Phase II Trial of Revlimid (Lenalidomide) and Low Dose Vidaza (Azacitidine) in Patients With Low - Intermediate-1 Risk Myelodysplastic Syndromes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Jun 2011 New trial record